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The N-end rule relates the in vivo half-life of a protein
to the identity of its N-terminal residue. We used an
expression-cloning screen to search for mouse proteins
that are degraded by the ubiquitin/proteasome-depend-
ent N-end rule pathway in a reticulocyte lysate. One
substrate thus identified was RGS4, a member of the
RGS family of GTPase-activating proteins that down-
regulate specific G proteins. A determinant of the RGS4
degradation signal (degron) was located at the N termi-
nus of RGS4, because converting cysteine 2 to either
glycine, alanine, or valine completely stabilized RGS4.
Radiochemical sequencing indicated that the N-termi-
nal methionine of the lysate-produced RGS4 was re-
placed with arginine. Since N-terminal arginine is a de-
stabilizing residue not encoded by RGS4 mRNA, we
conclude that the degron of RGS4 is generated through
the removal of N-terminal methionine and enzymatic
arginylation of the resulting N-terminal cysteine.
RGS16, another member of the RGS family, was also
found to be an N-end rule substrate. RGS4 that was
transiently expressed in mouse L cells was short-lived in
these cells. However, the targeting of RGS4 for degrada-
tion in this in vivo setting involved primarily another
degron, because N-terminal variants of RGS4 that were
stable in reticulocyte lysate remained unstable in L
cells.
A multitude of regulatory circuits, including those that con-
trol the cell cycle, cell differentiation, and responses to stress,
involve metabolically unstable proteins (1–5). A short in vivo
half-life of a regulator provides a way to generate its spatial
gradients and allows for rapid adjustments of its concentration,
or subunit composition, through changes in the rate of its
synthesis or degradation. Damaged or otherwise abnormal pro-
teins tend to be short-lived as well (6). Features of proteins that
confer metabolic instability are called degradation signals or
degrons (7, 8). The essential component of one degradation
signal, called the N-degron, is a destabilizing N-terminal resi-
due of a protein (9). A set of amino acid residues that are
destabilizing in a given cell yields a rule, called the N-end rule,
which relates the in vivo half-life of a protein to the identity of
its N-terminal residue. The N-end rule pathway is present in
all organisms examined, from mammals and plants to fungi
and prokaryotes (10, 11).
In eukaryotes, an N-degron consists of two determinants, a
destabilizing N-terminal residue and an internal lysine or ly-
sines (12–15). The Lys residue is the site of formation of a
multiubiquitin chain (16). The N-end rule pathway is thus one
of the pathways of the ubiquitin (Ub)1 system. Ub is a 76-
residue protein whose covalent conjugation to other proteins
plays a role in a vast range of biological processes (4, 5, 17). In
most of them, Ub acts through routes that involve the degra-
dation of ubiquitylated2 proteins by the 26 S proteasome, an
ATP-dependent multisubunit protease (18, 19).
The N-end rule has a hierarchic structure. In the yeast
Saccharomyces cerevisiae, Asn and Gln are tertiary destabiliz-
ing N-terminal residues in that they function through their
deamidation, by the NTA1-encoded3 N-terminal amidase (Nt-
amidase), to yield the secondary destabilizing residues Asp and
Glu (20). The destabilizing activity of N-terminal Asp and Glu
requires their conjugation, by the ATE1-encoded Arg-tRNA-
protein transferase (R-transferase), to Arg, one of the primary
destabilizing residues (21, 22). The primary destabilizing N-
terminal residues are bound directly by UBR1, also called
N-recognin, the E3 (recognition) component of the N-end rule
pathway (10, 11).
In mammals, the deamidation step is mediated by two Nt-
amidases, NtN-amidase and NtQ-amidase, which are specific,
respectively, for N-terminal Asn and Gln (23, 24). In verte-
brates, the set of secondary destabilizing residues contains not
only Asp and Glu but also Cys, which is a stabilizing residue in
yeast (25, 26). The mammalian counterpart of the yeast R-
transferase Ate1p exists as two distinct species, ATE1–1 and
ATE1–2, that are produced through alternative splicing of Ate1
pre-mRNA (27). Both ATE1–1 and ATE1–2 are similar in spec-
ificity to the ATE1-encoded yeast R-transferase, in that these
R-transferases can arginylate N-terminal Asp and Glu, but
cannot arginylate N-terminal Cys (27), suggesting the exist-
ence of a distinct R-transferase specific for N-terminal Cys.
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UBR1 (N-recognin) of yeast and mammals has two binding
sites for the primary destabilizing N-terminal residues of ei-
ther proteins or short peptides. The type 1 site is specific for the
basic N-terminal residues Arg, Lys, and His. The type 2 site is
specific for the bulky hydrophobic N-terminal residues Phe,
Leu, Trp, Tyr, and Ile (25, 28, 29). UBR1 contains yet another
substrate-binding site, which targets proteins bearing internal
(non-N-terminal) degrons. These proteins include CUP9 and
GPA1 in yeast (30–32) and the encephalomyocarditis virus 3C
protease in metazoans (33).
The known functions of the N-end rule pathway include the
control of peptide import in S. cerevisiae, through the degrada-
tion of CUP9, a transcriptional repressor of the peptide trans-
porter PTR2 (30) (this control includes a positive feedback
mediated by the type 1 and type 2 sites of UBR1 (31)); the
degradation of GPA1, one of two Ga proteins in S. cerevisiae
(32); and the degradation of alphaviral RNA polymerases and
other viral proteins in infected metazoan cells (33, 34). Physi-
ological N-end rule substrates were also identified among the
proteins secreted into the cytosol of the mammalian cell by
intracellular parasites such as the bacterium Listeria monocy-
togenes (35). Selective perturbation of the N-end rule pathway
was reported to interfere with mammalian cell differentiation
(36, 37) and with limb regeneration in amphibians (38). Studies
of the Ub-dependent proteolysis of endogenous proteins in mus-
cle extracts suggested that the N-end rule pathway plays a role
in catabolic states that result in muscle atrophy (39).
Until the present work, physiological substrates of Nt-ami-
dases and R-transferases were unknown in either yeast or
larger eukaryotes. Engineered N-end rule substrates, including
the substrates of Nt-amidases and R-transferases, can be pro-
duced in vivo through the Ub fusion technique, in which a
Ub-X-reporter fusion is cleaved, cotranslationally, after the last
residue of Ub by deubiquitylating enzymes (DUBs) (40), yield-
ing a reporter protein bearing the predetermined N-terminal
residue X (9, 10, 41).
In the present work, we employed a modification of the
cDNA-based sib-selection strategy in a transcription-transla-
tion lysate from rabbit reticulocytes (42, 43) to identify putative
physiological substrates of the N-end rule pathway. Specifi-
cally, we used dipeptides bearing destabilizing N-terminal res-
idues as selective inhibitors of the N-end rule pathway, and we
screened for mouse cDNAs that expressed proteins whose rel-
ative abundance in the lysate was altered in the presence of
relevant dipeptides.
Among the putative N-end rule substrates identified through
the use of this approach was mouse RGS4, a GTPase-activating
protein (GAP) for specific Ga subunits of heterotrimeric G
proteins, and a member of the family of RGS (regulator of G
protein signaling) proteins (44–50). We discovered that in ad-
dition to the expected removal of N-terminal Met from the
newly formed RGS4, the resulting N-terminal Cys of RGS4 was
arginylated, presumably by a distinct R-transferase whose Cys
specificity is different from that of the known R-transferases.
Thus modified RGS4 bore N-terminal Arg, a primary destabi-
lizing residue, and was degraded by the N-end rule pathway in
reticulocyte lysate.
EXPERIMENTAL PROCEDURES
Plasmids—The plasmids pcDNA3-Ub-X-nsP41–254 (where X is Met,
Arg, or Tyr) were used to express Ub-X-nsP41–254 fusions, denoted below
as Ub-X-nsP4*, from the phage T7 promoter in the transcription-trans-
lation reticulocyte lysate system by Promega (Madison, WI). The nota-
tion nsP41–254 refers to the 254-residue N-terminal fragment of the
69-kDa nsP4, the Sindbis virus RNA polymerase (34). The
pcDNA3-Ub-X-nsP41–254 plasmids were constructed using a set of open
reading frames (ORFs) encoding fusions between Ub and the full-length
nsP4 (51). The Ub-X-nsP4 ORFs in pJCEX1 (a gift from Dr. T. Ru¨-
menapf, Federal Research Center for Virus Diseases of Animals, Tu¨b-
ingen, Germany) were used as templates for PCR with two primers
59-TTCGGATCCGCCACCATGCAGATCTTCGTGAAGACCCTG-39 and
59-CCTTCTAGACTATGCGGTGACAAACTCAGTGGTAAT-39, to pro-
duce DNA fragments encoding Ub-X-nsP41–254 fusions (the underlined
sequences corresponded to the start and stop codons, respectively).
These fragments were digested with BamHI and XbaI and cloned into
the BamHI/XbaI-cut pcDNA3 vector (Invitrogen, Carlsbad, CA).
The plasmid pcDNA3-Ub-Lys-mCL expressed Ub-Lys-mCL, where
Lys-mCL was an N-terminally truncated large subunit of m-calpain
starting with Lys-10. The primers 59-ATTCCGCGGTGGCAAAGACC-
GCGAGGCGGCCGAGGGGCTG-39 and 59-CCTACTAGTCTATCATAG-
GACTGAAAAACTCAGCCACGAGAT-39 were used to amplify a DNA
fragment from pET24–80k, which contained cDNA encoding the large
subunit of rat m-calpain (52) (a gift from Dr. J. S. Elce, Queen’s Uni-
versity, Kingston, Ontario, Canada). The resulting fragment was di-
gested with SacII and SpeI and cloned into SacII/SpeI-cut
pcDNA3-Ub-Met-nsP41–254. The plasmids pcDNA3-p94 and
pcDNA3-p94C129A were used to express the mouse-specific calpain p94
and its C129A mutant. To produce these constructs, plasmids contain-
ing the rat p94 ORF and the p94C129A ORF (53) (gifts from Dr. H.
Sorimachi and Dr. K. Suzuki, University of Tokyo, Japan) were PCR-
amplified and cloned into the pcDNA3 vector.
The plasmid pcDNA-RGS4 was used for expression of the mouse
RGS4 in reticulocyte lysate and for transfection-mediated expression of
RGS4 in mouse L cells. This plasmid contained the T7 and CMV
promoters, and the mouse RGS4 ORF followed by two stop codons. The
RGS4 ORF was PCR-amplified from the plasmid pcDNA3-26-16-11 (see
below), using the primers 59-TTCGGATCCGCCACCATGTGCAAAGG-
ACTTGCAGGTCTG-39 and 59-CCTTCTAGATCATTAGGCACACTGG-
GAGACCAGGGA-39, followed by digestion with BamHI and XbaI and
cloning into BamHI/XbaI-cut pcDNA3 (the underlined sequences cor-
responded to the start codon and two stop codons, respectively). The
plasmids pcDNA3-RGS4M19A, pcDNA3-RGS4C2G, pcDNA3-RGS4C2V,
pcDNA3C2A, pcDNA3-RGS4K3R, pcDNA3-RGS4K3S, and pcDNA3-
RGS419–205, which expressed specific RGS4 mutants, were constructed
from pcDNA3-RGS4 using PCR-based site-directed mutagenesis (54).
The plasmid pcDNA3-RGS4M19A-GST expressed RGS4M19A-GST, a
fusion of RGS4M19A and glutathione transferase (GST). It was con-
structed through a PCR-mediated fusion of DNA fragments encoding
RGS4 and GST, followed by cloning into BamHI/XbaI-cut pcDNA3.
PCR-mediated site-directed mutagenesis was then used to introduce
the M19A mutation. The plasmid pcDNA3-RGS16, expressing mouse
RGS16 from the T7 promoter (55), and a PCR-produced fragment en-
coding mouse Gb5L were gifts from Dr. C. K. Chen and Dr. M. I. Simon
(California Institute of Technology, Pasadena, CA). The entire coding
regions of the final plasmid constructs were verified by DNA
sequencing.
In Vitro Transcription-Translation-Degradation System—The TNT
Quick-coupled Transcription-Translation System (Promega) contained
a rabbit reticulocyte lysate pre-mixed with most of the reaction compo-
nents necessary to carry out transcription/translation in the lysate,
including all of the amino acids except methionine. [35S]Methionine
(.1,000 Ci/mmol, Amersham Pharmacia Biotech) was used to label
newly formed proteins in the lysate. Proteins labeled with 3H-amino-
acids were produced in the TNT T7-coupled Reticulocyte Lysate (Pro-
mega), a version of the system where the main components of the
reaction were supplied separately. The reactions were set up according
to the manufacturer’s instructions. The reaction mixtures containing
dipeptides also contained 0.15 mM bestatin (Sigma), an inhibitor of
some aminopeptidases, to reduce degradation of the added dipeptides
(28). Stock samples of dipeptides were 0.5 M solutions in 10 mM K-
HEPES, pH 7.5. The reactions were incubated at 30 °C, unless stated
otherwise; they were terminated by the addition of SDS-sample buffer,
heated at 95 °C for 5 min, and fractionated by SDS-PAGE, followed by
autoradiography or fluorography. 35S in protein bands was determined
using PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Screening of Mouse cDNA Library of Small Pools in Rabbit Reticu-
locyte Lysate—Total RNA was isolated from the brains of female mice
with the guanidine thiocyanate method (54). Poly(A)1 RNA was puri-
fied using Oligotex mRNA kit (Qiagen, Valencia, CA) and was used to
synthesize oligo(dT)-primed double-stranded cDNA with the Super-
Script cDNA synthesis kit (Life Technologies, Inc.). After ligating the
DNA fragments to a BstXI adapter (Invitrogen, San Diego) and digest-
ing with NotI, the cDNAs were cloned into BstXI-NotI-cut pcDNA3. The
resulting cDNA library was introduced, by electroporation, into Esche-
richia coli SURE cells (Stratagene, La Jolla, CA), and the transfor-
mants were frozen in a number of samples. Titration of the library
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showed that it contained 3–4 3 106 independent clones. Pools of the
library cDNAs containing each about 50 clones were prepared as de-
scribed (42). Individual pools were added to the T7 TNT Quick-coupled
Transcription-Translation System (Promega) together with [35S]methi-
onine, in either the presence or the absence of the mixture of 5 mM
Arg-b-Ala, 5 mM Trp-Ala and 0.15 mM bestatin. All components of a
reaction except the lysate were gently mixed together, followed by the
addition of lysate. The reactions were performed in the total volume of
6.25 ml in a 96-well microtiter plate at 30 °C for 3.5 h. These conditions
were chosen after preliminary optimization, using Tyr-nsP4* as a test
protein. Once a cDNA pool was found to express a protein whose
relative abundance was increased in the presence of the dipeptides, the
pool was progressively subdivided and retested, until the isolation of a
single positive cDNA clone. One of the clones thus isolated, termed
pcDNA3-26-16-11, contained as ;3-kilobase pair mouse RGS4 cDNA
(see “Results”).
N-terminal Radiochemical Sequencing—RGS4M19A-GST was ex-
pressed in the TNT T7-coupled Reticulocyte Lysate System (Promega)
in the presence of either [3H]arginine (49 Ci/mmol), [3H]leucine (155
Ci/mmol), or [3H]lysine (87 Ci/mmol) (Amersham Pharmacia Biotech), 1
mM Arg-b-Ala, and 0.15 mM bestatin for 30 min at 30 °C, in the total
volume of 0.4 ml. The reaction was stopped by the addition of 20 mM
AMP-PNP (Sigma), a non-hydrolyzable ATP analog, and the labeled
RGS4M19A-GST was partially purified by affinity chromatography on
glutathione-Sepharose 4B (Amersham Pharmacia Biotech), followed by
SDS-10% PAGE and the electrophoretic transfer of separated proteins
in 10% methanol, 10 mM CAPS, pH 11, to Immobilon-P membrane
(Millipore, Burlington, MA). The transferred band of RGS4M19A-GST
was cut out (its position was determined with respect to stained protein
markers) and subjected to multiple cycles of Edman degradation, using
the 476A Applied Biosystems sequencer (Perkin-Elmer). The fractions
from each cycle were collected, and 3H in the fractions was determined
using a scintillation counter.
Transfections of Mouse L Cells and Pulse-Chase Assay—Transient
transfections of mouse L cells and pulse-chase analysis were performed
as described previously (56). The affinity-purified polyclonal antibody
raised against a peptide near the C terminus of RGS4 was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). In the experiments
with proteasome inhibitor MG132 (Calbiochem), it was added to cells,
at the final concentration of 50 mM, 45 min before the addition of
[35S]methionine and was present throughout the pulse-chase assay.
RESULTS
Degradation of N-end Rule Substrates in a Transcription-
Translation System Derived from Reticulocytes—The N-end
rule pathway can be selectively inhibited in reticulocyte lysates
through the addition of dipeptides bearing either type 1 or type
2 destabilizing N-terminal residues (25, 28). A commercially
produced transcription-translation system derived from reticu-
locyte lysate and containing the phage T7 RNA polymerase was
used to express a protein of interest from DNA template in one
reaction mixture. A putative N-end rule substrate in the lysate
was detected through its increased concentration in the pres-
ence of a cognate dipeptide inhibitor of the N-end rule pathway.
We began by examining the degradation of model N-end rule
substrates, which were derived from nsP4, the 69-kDa Sindbis
virus RNA polymerase, a physiological substrate of the mam-
malian N-end rule pathway that bears N-terminal Tyr (34).
The nsP4 protein is produced during Sindbis virus infection
through site-specific cleavage of the viral polyprotein precur-
sor. In the present work, the Ub fusion technique (9, 10, 51)
was used to synthesize, in reticulocyte lysate, a set of X-nsP4
derivatives that contained the first 254 residues of nsP4 and in
addition bore different residues at the Ub-nsP4 junction. These
test proteins, Ub-Arg-nsP41–254, Ub-Tyr-nsP41–254, and Ub-
Met-nsP41–254, are denoted below as Ub-Arg-nsP4*, Ub-Tyr-
nsP4*, and Ub-Met-nsP4*, respectively. Their N-terminal Ub
moiety was cotranslationally cleaved off by DUBs in the lysate
yielding Tyr-nsP4*, Arg-nsP4*, and Met-nsP4*, respectively.
Earlier experiments by T. Ru¨menapf have shown that these
constructs were N-end rule substrates in the transcription-
translation reticulocyte lysate.4
When a Ub-X-nsP4* fusion was expressed in reticulocyte
lysate and monitored as a function of time, a major band
corresponding to Ub-lacking X-nsP4* was observed (Fig. 1, A
and C). Although the electrophoretic mobility of X-nsP4* pro-
teins was slightly higher than expected from their predicted
molecular mass of 29 kDa, the observed proteins were clearly
X-nsP4*, rather than, for example, Ub-X-nsP4*, because the
removal of Ub occurs cotranslationally or nearly so (57), and
also because SDS-PAGE of the same samples using a more
concentrated polyacrylamide gel revealed the ;8-kDa band of
labeled free Ub (data not shown). In addition, the degradation
patterns of presumed X-nsP4* derivatives of Ub-X-nsP4* fu-
sions conformed to the N-end rule, as shown below.
The metabolically stable Met-nsP4* accumulated rapidly
during the first 30 min of the transcription-translation reaction
and reached a plateau around 30 min, because the protein
synthesis (but not the activity of the N-end rule pathway; see
below) ceased in the lysate by that time (Fig. 1, C and D). Thus,
in this setting, the incubation times in excess of ;30 min were
operationally equivalent to the “chase” part of a pulse-chase
experiment. In contrast to Met-nsP4*, the relative levels of
Arg-nsP4* (Fig. 1, A and B, lanes labeled c (controls)) and
Tyr-nsP4* (data not shown) began to decrease after 30 min,
reflecting their continuing degradation by the N-end rule path-
way. Arg and Tyr are, respectively, a type 1 (basic) and a type
2 (bulky hydrophobic) destabilizing residue in the N-end rule
(10). A ladder of higher molecular mass bands, apparently of
multiubiquitylated Arg-nsP4*, was observed with Arg-nsP4*
(Fig. 1A) but not with the metabolically stable Met-nsP4* (data
not shown).
The addition of Arg-b-Ala, a type 1 inhibitor of the N-end
rule pathway (25), strongly inhibited the ubiquitylation and
degradation of Arg-nsP4* (Fig. 1A, lanes labeled 1). The same
dipeptide had no effect on the degradation of Tyr-nsP4*, which
bore a type 2 destabilizing N-terminal residue (data not
shown). Conversely, Trp-Ala, a type 2 inhibitor, strongly de-
creased the degradation of Tyr-nsP4* (Fig. 2B) but had little
effect on the degradation of Arg-nsP4* (Fig. 1A, lanes labeled
2). At 1 mM, none of the several dipeptides tested, including
those bearing type 1, type 2, or type 3 destabilizing N-terminal
residues (25), affected the relative band intensity of Met-nsP4*
(Fig. 1, C and D), indicating that these dipeptides did not
perturb transcription and translation in this system. However,
at 10 mM, some of the dipeptides significantly delayed the
synthesis of X-nsP4* (data not shown). Therefore the experi-
ments were carried out with dipeptides at the initial concen-
tration of 1 mM. At this concentration, the inhibition of the
N-end rule pathway was strong but incomplete. The inhibition
of degradation of, for example, a type 1 substrate such as
Arg-nsP4* by a cognate dipeptide could be observed through
large differences in the amount of a test protein produced by 30
min, the time of cessation of protein synthesis in the lysate, and
through even larger differences at 60 min (Fig. 1B).
m-Calpain Bearing N-terminal Lysine Is Not a Substrate of
the N-End Rule Pathway—m-Calpain is a calcium-activated
cysteine protease composed of an 80-kDa large subunit (mCL)
and a 30-kDa small subunit (mCS) (58). The m- and m-calpains
are ubiquitously expressed in metazoan cells. In the presence of
Ca21, calpain subunits undergo autoproteolytic cleavages in
their N-terminal regions. The processed calpains have in-
creased activity. The in vitro autoproteolytic cleavage of mCL
was shown to remove the first 9 residues of mCL, yielding a
4 T. Ru¨menapf and A. Varshavsky, unpublished data.
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modified subunit, denoted below as Lys-mCL, which bears N-
terminal Lys (59), a type 1 destabilizing residue (10). We asked
whether Lys-mCL was unstable in reticulocyte lysate and, if so,
whether its instability required N-terminal Lys residue. A plas-
mid encoding the Ub-Lys-mCL fusion was constructed, and the
fusion was expressed in the transcription-translation lysate. It
was found that under standard conditions (in the absence of
added Ca21), the fusion-derived Lys-mCL was metabolically
stable in the lysate (Fig. 2A). In the presence of added Ca21 (2
mM), the newly formed Lys-mCL underwent rapid (apparently
autolytic) degradation in the lysate. Significantly, this Ca21-
induced degradation of Lys-mCL was not inhibited by Arg-b-
Ala, a type 1 inhibitor of the N-end rule pathway (Fig. 2). Thus,
the Lys-mCL derivative of the large subunit of m-calpain is not
a substrate of the N-end rule pathway in reticulocyte lysate,
despite the presence of a destabilizing N-terminal residue (see
“Discussion”).
The muscle-specific calpain p94 is homologous to the ubiqui-
tous calpains and was shown to be metabolically unstable (53,
60). We expressed rat p94 and its proteolytically inactive mu-
tant p94C129A in reticulocyte lysate. The full-length p94 was
rapidly cleaved in the lysate, yielding several fragments,
whereas proteolytically inactive p94C129A remained stable
(data not shown), in agreement with the earlier evidence (53).
Dipeptides Arg-b-Ala and Trp-Ala had no effect on the relative
yields of bands corresponding to either the full-length p94 or
the products of its autolysis (data not shown). Thus, neither
p94 nor its autolytically produced fragments are the substrates
of the N-end rule pathway.
Degradation of RGS4 in Reticulocyte Lysate Is Decreased by
Type 1 Inhibitors of the N-end Rule Pathway and by a Protea-
some Inhibitor—To search for putative N-end rule substrates
in a systematic way, we employed a modification of the previ-
ously developed in vitro screening method that involves the use
of small pools of cDNA clones (42, 43). A mouse brain cDNA
library was constructed, and about 500 mouse cDNA pools,
each containing about 50 cDNAs, were tested, sequentially, in
the transcription-translation reticulocyte lysate. Each reaction
was carried out in either the absence or the presence of a
mixture of two dipeptides, Arg-b-Ala and Trp-Ala, which have
been shown to inhibit selectively the degradation of engineered
N-end rule substrates in the lysate (Figs. 1, A and B, and 2B).
The resulting 35S-labeled proteins were visualized by SDS-
PAGE and autoradiography. We searched for protein bands
that were selectively enhanced in the presence, but not in the
absence, of the dipeptide inhibitors. A cDNA pool containing a
putative substrate of the N-end rule pathway was subjected to
subcloning, followed by re-analysis in the lysate. This proce-
dure yielded specific cDNAs encoding putative N-end rule
substrates.
Thus far, we found 7 cDNAs that encoded proteins whose
expression patterns identified them as putative substrates of
the N-end rule pathway. Most of these cDNAs encoded N-
terminally truncated polypeptides, produced by translation
from Met codons that were internal in the corresponding wild
type ORFs (data not shown). Although some of these truncated
proteins may prove to be physiologically relevant substrates of
the N-end rule pathway, we focused at first on a putative N-end
FIG. 1. Effects of dipeptides on the accumulation of Arg-nsP4* and Met-nsP4* in the transcription-translation reticulocyte lysate.
Plasmids expressing Ub-Arg-nsP4* (A) or Ub-Met-nsP4* (C) were added to reticulocyte lysate in the presence of [35S]methionine and either in the
absence of N-end rule inhibitors (lane c (controls)) or in the presence of either 1 mM Arg-b-Ala (lanes 1), or 1 mM Trp-Ala (lanes 2), or 1 mM Ala-Lys
(lanes 3), or 1 mM Lys-Ala (lanes 4), or 1 mM Ala-Arg (lanes 5). The samples in lanes 1–5 also contained 0.15 mM bestatin. The reactions were carried
out for 10, 20, 30, 60, 120, and 240 min, followed by SDS-PAGE, autoradiography, and quantitation. The position of R-nsP4* band and the
multi-Ub-containing species are indicated on the left. The positions of molecular mass markers are indicated on the right. B, relative amounts of
35S-labeled Arg-nsP4* in A were determined using PhosphorImager and were plotted as a function of incubation time. The amount of Arg-nsP4*
in the reaction without dipeptides at 30 min was assigned the value of 100. Control reaction are as follows: in the absence of dipeptides (M); in the
presence of Arg-b-Ala (L); in the presence of Trp-Ala (D); in the presence of Ala-Lys (f); in the presence of Lys-Ala (l); and in the presence of
Ala-Arg (). D, relative amounts of [35S]Met-nsP4* in C were determined and plotted as in B.
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rule substrate encoded by a full-length cDNA, which was found
to encode the mouse RGS4, a member of the RGS family of
GAPs for specific Ga subunits of G proteins (44, 45). The
;3-kilobase pair RGS4 mRNA contained the ;2-kilobase pair
long 39-untranslated region. To optimize the expression of
RGS4 in reticulocyte lysate, we constructed the plasmid
pcDNA3-RGS4, which contained the full-length RGS4 ORF,
followed by two stop codons, and lacked the wild type 39-
untranslated region of RGS4 mRNA. As with the original
RGS4 cDNA isolate (data not shown), the transcription-trans-
lation of pcDNA3-RGS4 yielded two protein bands, of 25 and 22
kDa (Fig. 3, A and D). The larger protein was the full-length
RGS4, whereas the smaller one was produced by translation
that started from a downstream Met (AUG) codon at amino
acid position 19, because pcDNA3-RGS4M19A, in which the
Met-19 codon was converted to an Ala codon, did not express
the lower protein band (Fig. 3D).
The RGS4 cDNA was initially picked by this screen because
upon the incubation times of 2–4 h, the lower (22-kDa) band
increased in intensity in the presence, but not in the absence, of
dipeptide inhibitors. However, this effect was later found to be
unrelated to the N-end rule pathway, as it was observed in the
presence of all dipeptides tested, including those that did not
inhibit the pathway (Fig. 3A). In contrast, at the incubation
times from 20 min to 1 h, the relative amount of the full-length
RGS4 increased up to 5-fold in the presence of either Arg-b-Ala
or Lys-Ala, the type 1 inhibitors of the N-end rule pathway
(Fig. 3, A and C), but not in the presence of Trp-Ala (type 2
inhibitor of the same pathway), or Ala-Lys and Ala-Arg (type 3
inhibitors) RGS4 (Fig. 4). A ladder of high molecular mass
bands, apparently of multiubiquitylated RGS4, was observed
above the RGS4 and RGS4M19A bands at 10, 20, and 30 min of
incubation (Fig. 3, A and B and data not shown). Arg-b-Ala and
Lys-Ala, but not the other tested dipeptides, delayed the ap-
pearance of multiubiquitylated RGS4 (Fig. 3, A and B). The
temporal pattern of inhibition of degradation of RGS4 by dipep-
tide inhibitors was similar to that described (and explained)
above for the engineered N-end rule substrate Arg-nsP4* (Fig.
1, A and B). Taken together, these data suggested that RGS4
was a type 1 substrate of the N-end rule pathway in reticulo-
cyte lysate.
At longer reaction times (either 2 or 4 h) the effect of type 1
N-end rule inhibitors on the relative level of RGS4 was not
observed (Fig. 3, A and C, and Fig. 4). By contrast, the band of
a model N-end rule substrate such as Arg-nsP4* was stronger
in the presence of Arg-b-Ala inhibitor at all reaction times,
including 2 and 4 h (Fig. 1B and Fig. 4). This difference in the
patterns of inhibition of RGS4 and Arg-nsP4* degradation
could be explained if, in contrast to Arg-nsP4*, there were two
pools of the newly formed RGS4 molecules, one of which un-
derwent rapid degradation, while the other remained long-
lived and accumulated during the chase, after ;30 min of
incubation. The fraction of short-lived RGS4 would be strongly
increased by the type 1 inhibitors Arg-b-Ala or Lys-Ala at the
early times of incubation (before ;1 h), but over longer times
(from 1 to 4 h) this degradation-susceptible form of RGS4 would
still be degraded in the lysate, presumably because of incom-
plete inhibition of the N-end rule pathway by dipeptides, in
addition to gradual destruction of the dipeptides by peptidases
in the lysate. Thus, at reaction times of 2 h or longer, only the
subset of long-lived RGS4 molecules remained.
The fraction of short-lived RGS4 comprised 75–80% of the
total RGS4; the remainder of RGS4 molecules (15–25%) was
long-lived. This estimate stemmed from the fact that at 30 min,
the amount of RGS4 was 4 to 5 times higher in the presence of
Arg-b-Ala than in its absence (Fig. 3C, Fig. 4, and data not
shown). (That the effect of Arg-b-Ala did not result from its
influence on the rates of transcription/translation in the lysate
was indicated by control experiments with the long-lived Met-
nsP4* (Fig. 1, C and D).) In contrast to RGS4, most Arg-nsP4*
molecules were short-lived in the lysate. As a result, the rela-
tive amount of Arg-nsP4* was higher in the presence of Arg-b-
Ala than in its absence throughout the 4-h incubation (Fig. 4),
although the amount of Arg-nsP4* continued to decline after
1 h even in the presence of Arg-b-Ala (Fig. 1), for the reasons
described above.
We also examined the effect of a proteasome inhibitor,
MG115 (61), on the degradation of RGS4 and Arg-nsP4* in the
lysate. MG115 at 10 mM markedly increased the levels of both
RGS4 and Arg-nsP4* at the incubation times shorter than 1 h
(Fig. 5, A–D). MG115 at 0.1 mM further increased the amounts
of RGS4 and Arg-nsP4* at these incubation times (Fig. 5, A–D).
In addition, the ladders of apparently multiubiquitylated RGS4
and Arg-nsP4* were enhanced in the presence of MG115 (Fig.
5, A and C), in contrast to the effect of N-end rule inhibitors,
which decreased the relative level of multi-Ub ladders (Fig.
3B). These patterns were consistent with MG115 inhibiting
post-ubiquitylation steps of the proteasome-mediated degrada-
tion of RGS4 and Arg-nsP4*, in contrast to the action of dipep-
tides, which inhibited pre-ubiquitylation steps (25, 61).
Similarly to the effects of dipeptide inhibitors (Fig. 1), the
proteasome level inhibition by MG115 was also incomplete and
resulted in a gradual decrease of the RGS4 and Arg-nsP4*
levels after 30 min of incubation (Fig. 5). Note that this de-
crease led to the nearly complete disappearance of Arg-nsP4*
by 4 h of incubation, whereas in the case of RGS4 the decrease
stopped when 20–25% of RGS4 still remained in the lysate
(Fig. 5, B and D). These data provided independent evidence for
the existence of a degradation-resistant fraction of RGS4. In
summary, we identified mouse RGS4 as a type 1 substrate of
the N-end rule pathway in the reticulocyte lysate.
FIG. 2. Lys-mCL is not an N-end rule substrate in reticulocyte
lysate. A, plasmid DNA encoding a Ub-Lys-mCL, a Ub fusion to a
derivative of the large m-calpain subunit bearing N-terminal Lys (see
“Results”), was expressed in the transcription-translation reticulocyte
lysate in the presence of [35S]methionine. The reaction was allowed to
proceed for 20 min at 37 °C (“pulse”). Thereafter, cycloheximide and
unlabeled L-methionine were added to all samples, to the final concen-
trations of 0.1 mg/ml and 0.5 mM, respectively. CaCl2 and/or Arg-b-Ala
were added to some of the samples, to the final concentrations of 2 and
2.5 mM, respectively. 0.15 mM bestatin was present in these samples as
well. The reactions mixtures were incubated for the indicated chase
times of 0, 1, or 2 h, followed by SDS-PAGE and autoradiography. B,
plasmid DNA encoding Ub-Tyr-nsP4* was expressed in the lysate, and
the reactions were allowed to proceed as in A except that Trp-Ala was
added, instead of Arg-b-Ala, after the pulse. The positions of (deubiq-
uitylated) Lys-mCL and Tyr-nsP4* bands are as indicated at the right.
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The Degradation Signal of RGS4 Is a Cysteine-based N-
degron—The N-terminally truncated RGS4, produced through
translation initiation at the second (Met-19) start codon of the
RGS4 ORF (see above), was not a substrate of the N-end rule
pathway, because degradation of this RGS419–205 derivative in
the lysate was not selectively decreased by dipeptide inhibitors
of the N-end rule pathway (Fig. 3A and data not shown). This
finding strongly suggested that the UBR1-dependent degron of
the full-length RGS4 was located near its N terminus. The
deduced N-terminal sequence of RGS4 is Met-Cys-Lys-Gly-
(62). Extensive evidence indicates that cytosolic methionine
aminopeptidases (MetAPs), a class of proteases present in all
organisms, cleave off N-terminal Met from proteins and short
peptides depending largely on the identity of the next residue,
which becomes N-terminal after the cleavage. In particular,
MetAPs rapidly (cotranslationally) cleave Met off N-terminal
sequences beginning with Met-Cys (63–65). Cys is a stabilizing
residue in prokaryotes and in the yeast S. cerevisiae but a
secondary destabilizing residue in the metazoan N-end rule
pathway (25, 26). Specifically, the destabilizing activity of N-
terminal Cys is tRNA-dependent, strongly suggesting that an
Arg-tRNA-protein transferase (R-transferase) conjugates Arg,
a primary destabilizing residue, to the N-terminal Cys of an
N-end rule substrate (25). This, and the fact that the degrada-
tion of RGS4 was inhibited by type 1 but not by type 2 dipep-
tides (Fig. 3), suggested the following model: the N-terminal
Met of newly formed RGS4 is removed by MetAPs; the result-
ing N-terminal Cys is arginylated by R-transferase, and the
arginylated RGS4 is targeted for degradation by the UBR1-
encoded E3a and the rest of the N-end rule pathway.
One prediction of this model was that a significant fraction of
RGS4 in the reticulocyte lysate should contain the N-terminal
sequence Arg-Cys-Lys-Gly-, as distinguished from either Cys-
Lys-Gly- or the encoded sequence Met-Cys-Lys-Gly-. Another
prediction was that a mutational replacement of Cys-2 with a
stabilizing residue that still allows the efficient removal of
N-terminal Met should make the resulting RGS4 variant long-
lived in the lysate. We tested both predictions.
Since the conventional N-terminal sequencing of RGS4 pro-
duced in the lysate would have required a major scale up of the
reaction protocol, we employed radiochemical sequencing. A
plasmid encoding RGS4M19A fused to glutathione transferase
(GST) was constructed. The RGS4M19A-GST protein was ex-
pressed in the lysate and was found to be degraded by the
N-end rule pathway indistinguishably from the unmodified
RGS4 (data not shown). The M19A mutation was introduced to
preclude the formation of N-terminally truncated RGS4 vari-
ant (Fig. 3, A and D). RGS4M19A-GST was synthesized in the
lysate in the presence of Arg-b-Ala (type 1 inhibitor of the
N-end rule pathway) and either [3H]arginine, [3H]lysine, or
[3H]leucine. The resulting 3H-labeled RGS4M19A-GST proteins
were purified using glutathione-Sepharose affinity chromatog-
FIG. 3. Type 1 dipeptides Arg-b-Ala and Lys-Ala inhibit degradation and ubiquitylation of RGS4 in reticulocyte lysate. A, the
plasmid pcDNA3-RGS4 (see “Experimental Procedures”) was expressed in the transcription-translation reticulocyte lysate in the presence of
[35S]methionine and either in the absence of dipeptides (lanes c) or in the presence of 1 mM Arg-b-Ala (lane 1), 1 mM Trp-Ala (lane 2), 1 mM Ala-Lys
(lane 3), 1 mM Lys-Ala (lane 4), and 1 mM Ala-Arg (lane 5). Dipeptide-containing samples also contained 0.15 mM bestatin. The reactions were
carried out for 10, 20, 30, 60, 120, and 240 min, followed by SDS-PAGE, autoradiography, and quantitation. The positions of mouse RGS4 and the
multi-Ub-containing species are indicated on the left. An asterisk marks the N-terminally truncated RGS4 derivatives, which were produced
through alternative translational initiation from the internal start codon at the Met-19 position of RGS4. The positions of molecular mass markers
are indicated on the right. B, autoradiographic overexposure of the 20-min part of B to visualize the ladders of multi-Ub-containing species. C,
relative amounts of 35S-RGS4 in A were determined using PhosphorImager and were plotted as a function of incubation time. The amount of RGS4
in the reaction without dipeptides at 30 min was assigned the value of 100. Control reactions were as follows: in the absence of dipeptides (M); in
the presence of Arg-b-Ala (L); in the presence of Trp-Ala (D); in the presence of Ala-Lys (f); in the presence of Lys-Ala (l); and in the presence
of Ala-Arg (). D, plasmids encoding either wild type RGS4 (wt), or RGS4M19A, or RGS419–205 were expressed in the lysate either in the absence
of dipeptides (lane c), or in the presence of 1 mM Arg-b-Ala and 0.15 mM bestatin (lane 1), or in the presence of 1 mM Trp-Ala and 0.15 mM bestatin
(lane 2).
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raphy and SDS-PAGE. The band of RGS4M19A-GST was sub-
jected to automated Edman degradation, and 3H released in
each cycle was determined.
RGS4M19A-GST labeled with [
3H]arginine yielded a major
peak of 3H in the first Edman cycle, followed by a second peak
in the cycle 14, consistent with Arg at positions 1 and 14 (Fig.
6A). Whereas Arg at position 1 would have to be conjugated to
RGS4 posttranslationally, as predicted by the above model, the
first encoded Arg residue of RGS4 was, in fact, located at the
encoded position 14 of arginylated RGS4 (in the sequence
frame that begins with Arg-Cys-Lys-Gly-) (Fig. 6A). This ex-
periment was carried out twice, with two independent prepa-
rations of [3H]RGS4M19A-GST, and gave the same result.
RGS4M19A-GST labeled with [
3H]lysine yielded virtually no at
position 1 but produced a major peak at position 3 and eleva-
tions at positions 17 and 20, consistent with the known posi-
tions of three Lys residues in the N-terminal sequence of argi-
nylated RGS4 (Fig. 6B). RGS4M19A-GST labeled with
[3H]leucine yielded no 3H in the cycle 1 but produced peaks in
the cycles 5 and 8, once again consistent with the known
positions of two Leu residues in the N-terminal sequence of
arginylated RGS4 (Fig. 6C). Taken together, these independent
sets of radiochemical sequencing data indicated that the bulk of
RGS4 produced in reticulocyte lysate indeed bore the N-termi-
nal sequence Arg-Cys-Lys-Gly-, with the Arg residue of this
sequence not encoded by RGS4 mRNA.
To verify the second prediction of the model, we constructed
several mutant alleles of RGS4 and expressed them in the
lysate in either the absence or presence of N-end rule inhibitors
(Fig. 7). It was found that the replacement of Cys-2 with either
Gly, Val, or Ala residues completely stabilized the resulting
RGS4C2G, RGSC2V, and RGS4C2A in the lysate (Fig. 7), in agree-
ment with the model’s prediction. We also converted Lys-3 of
RGS4 into either Ser or Arg. Interestingly, whereas the Lys3
Ser replacement completely stabilized the resulting RGS4K3S
variant, the Lys 3 Arg replacement had no effect on the deg-
radation of RGS4K3R (Fig. 7). Thus, although Lys-3 is not
required for ubiquitylation of RGS4 (since it could be replaced
with the non-ubiquitylatable Arg), the presence of a basic res-
idue (either Lys or Arg) at position 3 (position 2 after the
removal of N-terminal Met) is required for the RGS4 degrada-
tion by the N-end rule pathway.
The fact that RGS4K3S, which bears N-terminal Cys and
differs from RGS4 exclusively at position 3 (Lys3 Ser replace-
ment), was stable in the lysate (Fig. 7) indicated that the
presence of N-terminal Cys was not sufficient for making a
protein an N-end rule substrate. To explore this issue with
other natural proteins, we expressed in the lysate the mouse
protein Gb5L, a member of the family of b subunits of hetero-
trimeric G proteins (66). The predicted N-terminal sequence of
Gb5L is (Met)-Cys-Asp-Gln-Thr-. We found that Arg-b-Ala, the
type 1 inhibitor of the N-end rule pathway, had no effect on the
FIG. 4. The relative levels of RGS4 and engineered N-end rule
substrates in the presence of cognate dipeptide inhibitors in
reticulocyte lysate. E, the ratios, denoted as dipeptides/controls (D/
C), of the relative amounts of RGS4 in the presence versus the absence
of 1 mM Arg-b-Ala, as a function of time in the lysate. These ratios were
calculated from the data in Fig. 3C. L, the analogous ratio curve but for
Tyr-nsP4* in the presence of 1 mM Trp-Ala (primary data not shown).
M, the analogous ratio curve but for Arg-nsP4* in the presence of 1 mM
Arg-b-Ala (calculated from the data in Fig. 1B; the 4-h ratio could not be
determined reliably because of too low 35S in the band of Arg-nsP4* in
the absence of dipeptides). Note the monotonous increase of the dipep-
tides/controls ratio for engineered N-end rule substrate but not for
RGS4.
FIG. 5. Proteasome inhibitor MG115
decreases degradation of RGS4 and
Arg-nsP4* in reticulocyte lysate.
RGS4 (A) and Arg-nsP4* (C) were ex-
pressed in the transcription-translation
reticulocyte lysate in the presence of
[35S]methionine and either in the absence
of MG115 (Me2SO solvent alone; lanes c)
or in the presence of 10 mM (lane 1) and
100 mM (lane 2) MG115. The reactions
were carried out for 10, 20, 30, 60, 120,
and 240 min, followed by SDS-PAGE, au-
toradiography, and quantitation. The po-
sitions of RGS4 and Arg-nsP4* bands and
of the ladder of multi-Ub-containing spe-
cies are indicated on the left. B, relative
amounts of 35S-RGS4 in A were deter-
mined using PhosphorImager and were
plotted as a function of incubation time.
The amount of RGS4 in the reaction with-
out MG115 at 30 min was assigned the
value of 100. M, control reaction, in the
absence of MG115; L, in the presence of
10 mM MG115; D, in the presence of 100
mM MG115. D, the same as in B but for
Arg-nsP4*.
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pattern of accumulation of Gb5L in reticulocyte lysate (data not
shown).
The encoded N-terminal sequence of RGS4 is similar to those
of RGS5 and RGS16; the similarities include Cys-2 and a basic
residue at position 3 (55, 67). To test whether RGS16 was an
N-end rule substrate, we expressed RGS16 in reticulocyte ly-
sate. As shown in Fig. 8A, the relative amount of RGS16 was
indeed significantly higher in the presence of Arg-b-Ala (type 1
inhibitor) than either in the presence of Trp-Ala (type 2 inhib-
itor) or in the absence of dipeptides. The temporal pattern of
the inhibitor-produced increase in the RGS16 concentration
was similar to that described for RGS4 in Fig. 3B (note the 30-
and 60-min points in Fig. 8A). The effect of Arg-b-Ala on the
accumulation of RGS16 (Fig. 8A), although significant, was
smaller than its effect on the accumulation of RGS4 (Fig. 3A).
Longer autoradiographic exposures showed the ladders of
multi-Ub chains, apparently conjugated to RGS16 (Fig. 8B).
Consistent with the weaker effect of Arg-b-Ala, the relative
level of RGS16-specific multi-Ub chains (in the absence of in-
hibitors) was lower than that of RGS4-specific multi-Ub chains
(Figs. 3A and 8B and data not shown). Finally, the ubiquityla-
tion of RGS16 was significantly delayed in the presence of
Arg-b-Ala (type 1 inhibitor) but not in the presence of Trp-Ala
(type 2 inhibitor) (Fig. 8B). Taken together, these data (Fig. 8)
indicated that RGS16 was also a substrate of the N-end rule
pathway in reticulocyte lysate.
RGS4 Is Metabolically Unstable in Vivo—A mouse RGS4-
expressing plasmid was transiently transfected into mouse L
cells, and the metabolic stability of RGS4 was measured in a
pulse-chase assay, using an antibody to RGS4. The transiently
expressed RGS4 was found to be short-lived in L cells, with the
half-life of 40–50 min (Fig. 9, A and B). When L cells were
treated with the proteasome inhibitor MG132, both before and
during pulse-chase, RGS4 was significantly stabilized (Fig. 9, A
and B). Thus, similarly to the results with reticulocyte lysate,
the in vivo degradation of RGS4 was proteasome-dependent.
To verify whether the degradation of RGS4 in vivo required
its Cys-based N-degron, L cells were transfected with the plas-
FIG. 6. Radiochemical N-terminal sequencing of RGS4 pro-
duced in the reticulocyte lysate. RGS4M19A-GST was synthesized in
the transcription-translation reticulocyte lysate for 30 min in the pres-
ence of 1 mM Arg-b2Ala and one of the 3H-containing amino acids:
[3H]arginine (A), [3H]lysine (B), or [3H]leucine (C). The resulting 3H-
labeled RGS4M19A-GST was purified by affinity chromatography and
SDS-PAGE, followed by radiochemical N-terminal sequencing through
Edman degradation, as described under “Experimental Procedures.”
Plotted are the amounts of 3H (cpm) recovered in each Edman cycle. The
inferred N-terminal sequence of RGS4M19A-GST (see “Results”) is
shown at the top of each panel, with the expected 3H residues high-
lighted in bold.
FIG. 7. Single residue substitutions at the N terminus of RGS4
abolish its degradation in reticulocyte lysate. Wild type mouse
RGS4 and the indicated single residue derivatives of RGS4p were
expressed in the transcription-translation reticulocyte lysate in the
presence of [35S]methionine and either in the absence of N-end rule
inhibitors (lane c), or in the presence of 1 mM Arg-b-Ala (lane 2), or in
the presence of 1 mM Trp-Ala (lane 2). Dipeptide-containing samples
also contained 0.15 mM bestatin. The reactions were carried out for 15,
30, 60, and 120 min, followed by SDS-PAGE and autoradiography.
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mids expressing the RGS4C2G and RGS4C2V mutants, and the
in vivo decay curves of these proteins were compared with that
of wild type RGS4. It was found that these variants of RGS4,
which were completely stable in reticulocyte lysate (Fig. 7),
were degraded in L cells similarly to wild type RGS4 (data not
shown).
DISCUSSION
We searched for substrates of the mammalian N-end rule
pathway by testing some of the previously known candidates
and also by employing a modification of the sib selection-based
in vitro screen (42, 43) in a transcription-translation reticulo-
cyte lysate. Two N-end rule substrates thus identified were
mouse RGS4 and RGS16. These proteins are members of the
RGS family of GTPase-activating proteins (GAPs) that down-
regulate specific G proteins (44–50, 67). We report the follow-
ing results.
1) The in vitro activated, proteolytically processed larger (80
kDa) subunit of the cysteine protease m-calpain was previously
shown to bear N-terminal Lys (59), a type 1-destabilizing res-
idue in the N-end rule (10). We expressed this subunit, termed
Lys-mCL, in the reticulocyte lysate as a Ub-Lys-mCL fusion.
The resulting Lys-mCL was not a substrate of the N-end rule
pathway, despite the presence of a destabilizing N-terminal
residue. Since an N-degron is a bipartite signal (12, 13, 15), the
absence of active N-degron from Lys-mCL could be due to the
absence of a targetable internal Lys residue, the second deter-
minant of an N-degron. Another possibility is a steric hin-
drance in the binding of UBR1 to the N-terminal lysine of
Lys-mCL. Thus, a destabilizing N-terminal residue is not the
sole essential determinant of an active N-degron, as demon-
strated previously with engineered N-end rule substrates (12).
2) A major fraction (75–85%) of mouse RGS4 synthesized in
reticulocyte lysate was rapidly degraded by a pathway that was
proteasome-dependent and apparently also Ub-dependent. The
other 15–25% of the newly made RGS4 was found to be stable
in the lysate.
3) The degradation of RGS4 was inhibited by dipeptides
bearing type 1-destabilizing N-terminal residues (Arg-b-Ala or
Lys-Ala) but was unaffected by dipeptides bearing a type 2-de-
stabilizing N-terminal residue (Trp-Ala) or a type 3 residue
(Ala-Lys and Ala-Arg).
4) Radiochemical sequencing of RGS4 produced in reticulo-
cyte lysate and labeled with either [3H]arginine, [3H]lysine, or
[3H]leucine revealed the presence of posttranslationally conju-
gated Arg at the N terminus of RGS4. The deduced N-terminal
sequence of RGS4 was Met-Cys-Lys-Gly-. The observed/in-
ferred sequence was Arg-Cys-Lys-Gly-. This result and, inde-
pendently, the fact that degradation of RGS4 was inhibited by
type 1 but not by type 2 dipeptides strongly suggested the
following model: the N-terminal Met of newly formed RGS4 is
removed by MetAPs; the resulting N-terminal Cys is arginy-
lated by R-transferase; and the arginylated RGS4 is targeted
for processive degradation by the UBR1-encoded E3a and the
rest of the N-end rule pathway.
5) In agreement with a prediction of this model, the degra-
dation of RGS4 in reticulocyte lysate was found to require
Cys-2 residue, which becomes N-terminal after the MetAP-
mediated cotranslational removal of Met. Specifically, the
RGS4 mutants C2G, C2V, and C2A, in which Cys-2 was re-
placed with Gly, Val or Ala, were completely stable in the
lysate. The former two residues are stabilizing in the N-end
rule, and neither of the 3 residues is expected to interfere with
the removal of N-terminal Met by MetAPs (64).
6) A Lys 3 Ser replacement at the encoded position 3 of
RGS4 also completely stabilized the resulting RGS4K3S pro-
tein. However, a Lys3 Arg replacement at this position had no
effect on the degradation of RGS4K3R. Thus, Lys-3 is not re-
quired for ubiquitylation of RGS4. However, the presence of a
basic residue (either Lys or Arg) immediately after Cys is
FIG. 8. Type 1 N-end rule inhibitor decreases degradation and
ubiquitylation of RGS16 in reticulocyte lysate. A, RGS16 was
expressed in the transcription-translation reticulocyte lysate in the
presence of [3H]leucine and either in the absence of N-end rule inhibi-
tors (lane c) or in the presence of 1 mM Arg-b-Ala (lane 1) or 1 mM
Trp-Ala (lane 2). Dipeptide-containing samples also contained 0.15 mM
bestatin. The reactions were carried out for 10, 20, 30, 60, 120, and 240
min, followed by SDS-PAGE and fluorography. B, the same as in A, but
with autoradiographic overexposure to visualize the ladders of multi-
Ub-containing species.
FIG. 9. In vivo degradation of RGS4
in transiently transfected mouse L
cells. A, L cells were transfected with an
RGS4-expressing plasmid (see “Experi-
mental Procedures”). Cells were preincu-
bated in methionine-free medium for 45
min and then labeled for 12 min with
[35S]methionine/cysteine and chased for
0, 1, or 2 h. Either 50 mM MG132 (from a
stock solution in Me2SO) or the equiva-
lent amount of Me2SO were present dur-
ing both preincubation in methionine-free
medium and the pulse-chase. Cell ex-
tracts were immunoprecipitated with an-
ti-RGS4 antibody, followed by SDS-PAGE
and autoradiography. B, the pattern in A
was quantitated using PhosphorImager.
The amount of 35S in RGS4 at time 0 (end
of the pulse) was taken as 100%. M, no
proteasome inhibitor; circo, in the pres-
ence of 50 mM MG132.
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essential for the RGS4 degradation by the N-end rule pathway.
One possibility is that the requirement for a basic residue at
this position reflects the substrate specificity of an uncharac-
terized R-transferase that arginylates the N-terminal Cys.
7) The mouse protein Gb5L, a member of the family of b
subunits of heterotrimeric G proteins (66) that bore the (initial)
N-terminal Met-Cys, was tested and found not to be an N-end
rule substrate, similarly to the RGS4K3S mutant, which also
bore the (initial) N-terminal sequence Met-Cys but was not
degraded by the N-end rule pathway. Thus, the N-terminal Cys
of wild type RGS4 is an essential determinant of its N-degron,
but other N terminus-proximal residues are relevant as well.
8) Similarities among the N-terminal sequences of RGS4,
RGS5, and RGS16 (67) suggested that RGS5 and RGS16 may
also be N-end rule substrates. This prediction was tested, thus
far, with RGS16, and was confirmed.
9) RGS4 was transiently expressed in mouse L cells and
found to be an unstable protein, with the half-life of 40–50 min.
The in vivo degradation of RGS4 was proteasome-dependent,
as indicated by the nearly complete stabilization of RGS4 in the
presence of proteasome inhibitor MG132. However, the target-
ing of RGS4 in this in vivo setting involved primarily a degron
distinct from the Cys-based N-degron, because N-terminal
variants of RGS4 such as RGS4C2V and RGS4C2G, which were
completely stable in reticulocyte lysate, remained unstable in L
cells.
We consider the latter result first. 15–25% of the reticulocyte
lysate-produced RGS4 was resistant to degradation by the N-
end rule pathway (paragraph 2 above). An analogous protec-
tion of RGS4 against targeting by the N-end rule pathway in L
cells might involve a much higher fraction of the newly formed
RGS4. The mechanism of protection may be a modification of
the N-terminal Cys, for example, its palmitoylation (45, 47, 62,
67) or acetylation (68) that would be expected to preclude the
arginylation and degradation of RGS4 by the N-end rule path-
way. Thus it is possible, indeed likely, that there is a kinetic
competition among these reactions at the N-terminal Cys of a
nascent RGS4 protein. In experiments to address this model,
we added varying amounts of acetyl-CoA or palmitoyl-CoA (the
substrates of N-terminal acetylases and palmitoyltransferases)
to reticulocyte lysate; no effect of the added compounds on the
degradation of newly formed RGS4 in the lysate was observed.5
A second possibility is a spatial localization of RGS4 in L cells
that protects it from degradation by the N-end rule pathway
but leaves RGS4 still targetable by another proteasome-de-
pendent pathway(s) that is inactive in reticulocytes. Yet an-
other possible reason for the difference between the results
with reticulocyte lysate versus L cells is that the cysteine
branch of the N-end rule pathway may be cell type-specific; for
example, a Cys-specific R-transferase is present in reticulo-
cytes but might be expressed at a lower level in L cells. In
recent experiments, RGS4 was expressed in Xenopus laevis
oocytes, through microinjection of RGS4 mRNA. It was found
that, similarly to the results with reticulocyte extracts, RGS4
was degraded in oocytes by the cysteine branch of the N-end
rule pathway.6
One difficulty in identifying physiological N-end rule sub-
strates (as distinguished from those produced through the Ub
fusion technique (10)) is caused by the fact that MetAPs remove
N-terminal Met from newly formed proteins if, and only if, the
second residue in a polypeptide chain is stabilizing in the
yeast-type N-end rule. Specifically, the known MetAPs remove
N-terminal Met if the second position residues are Gly, Val,
Ala, Ser, Thr, Cys, or Pro (63–65). All of these residues are
stabilizing in the yeast-type N-end rule (10). Therefore, a nat-
ural substrate of an N-end end rule pathway that bears an
N-degron in, for instance, S. cerevisiae cells can be produced
exclusively through cleavages (anywhere along the polypeptide
chain) by proteases distinct from MetAPs. An example of N-end
rule substrate of this class is the S. cerevisiae protein SCC1, a
subunit of the cohesin complex that holds together sister chro-
matids. In a reaction that requires ESP1, the 566-residue SCC1
is cleaved (at the time of sister chromatid separation) at posi-
tions 180 and/or 268, resulting in fragments that bear N-ter-
minal Arg, a type 1-destabilizing residue (69). These fragments
were found to be degraded by the N-end rule pathway in vivo.7
The situation in metazoans such as mammals is similar to
the one in yeast, in that the yeast-type destabilizing residues
cannot be exposed at the N termini of mammalian proteins
through cleavages by the known MetAPs (10, 64). The differ-
ence here is that Cys, Ala, Ser, Thr, and Pro are stabilizing
residues in yeast but destabilizing in mammalian cells (10, 25,
70). In contrast to the other destabilizing residues, the second
position Cys, Ala, Ser, Thr, and Pro can be efficiently exposed
at the N termini of newly formed proteins through the action of
MetAPs. Of these five residues, N-terminal Cys is a special
case; its destabilizing activity requires its posttranslational
conjugation to Arg, a primary destabilizing residue recognized
by the type 1 site of UBR1 (E3a) (10).
The finding of the dependence of destabilizing activity of
N-terminal Cys on the presence of tRNA (25, 26), and the
identification, in the present work, of Arg as the posttransla-
tionally linked N-terminal residue of mouse RGS4, indicated
the existence of an Arg-tRNA-protein transferase (R-transfer-
ase) that conjugates Arg to N-terminal Cys. This R-transferase
is distinct from the two previously characterized mammalian
R-transferases, both of which are encoded by the alternatively
spliced ATE1 gene (27). The two forms of mouse ATE1 R-
transferase have different specific activities but apparently the
same substrate specificity; similarly to their S. cerevisiae hom-
olog, they arginylate N-terminal Asp and Glu but cannot argi-
nylate N-terminal Cys (27).
The ;20 known proteins of the mammalian RGS family have
in common the ;130-residue RGS domain that binds to Ga
subunits and is responsible for the GAP function of RGS pro-
teins (44, 45). As would be expected of pleiotropic regulators at
key junctions of the cellular metabolism, the activity of RGS
proteins is controlled at several levels, including regulation of
their synthesis and localization (44). It is becoming increas-
ingly clear that the (conditional) degradation of RGSs is yet
another way in which the activity of these proteins is modu-
lated in cells. Besides RGS4 and RGS16 of the present work,
one other member of the family, RGS7, was recently shown to
be unstable in vivo (71, 72). The normally short-lived RGS7 is
stabilized through its interaction with polycystin, a PKD1-
encoded protein involved in polycystic kidney disease (71). The
degradation of RGS7 is also decreased upon exposure of cells to
tumor necrosis factor a; the resulting increase in the concen-
tration of RGS7 may contribute to sepsis-induced changes in
the nervous system (72). The degradation signal(s) of RGS7
remains to be characterized.
Our major results are the findings that RGS4 and RGS16
(and possibly also RGS5) are substrates of the cysteine branch
of the N-end rule pathway and that the Cys-based N-degron of
these proteins functions through the posttranslational arginy-
lation of N-terminal Cys by an unidentified, apparently Cys-
specific R-transferase. RGS4 and RGS16 are the first physio-
5 I. Davydov and A. Varshavsky, unpublished data.
6 J. Sheng, I. Davydov, and A. Varshavsky, unpublished data. 7 H. Rao and A. Varshavsky, unpublished data.
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logical substrates of the N-end rule pathway that bear a
secondary destabilizing N-terminal residue, which functions
through its conjugation to Arg, a primary destabilizing residue.
Specific functions of the metabolic instability of RGS4 and
RGS16 remain to be understood. One route to these functions is
through the cloning of Cys-specific R-transferase and construc-
tion of mouse strains that lack this enzyme and (therefore) the
cysteine branch of the N-end rule pathway. It would also be
important to define, in detail, Cys-proximal N-terminal se-
quences in proteins that promote the arginylation of N-termi-
nal Cys. This information will facilitate the identification of
Cys-specific N-end rule substrates in data bases of protein
sequences.
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